Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 10/20 | 1.00 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.98 |
| ▸ | P2RY2 | P41231 | 8/20 | 0.98 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.98 |
| ▸ | OGT | O15294 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29396726 | 1.00 | P2RY14 (1.00) | P2RY14P2RY6P2RY2P2RY4OGT | |
| SCHEMBL29441461 | 1.00 | P2RY14 (1.00) | P2RY14P2RY6P2RY2P2RY4OGT | |
| SCHEMBL12377962 | 1.00 | P2RY14 (1.00) | P2RY14P2RY6P2RY2P2RY4OGT | |
| SCHEMBL15433957 | 1.00 | P2RY14 (1.00) | P2RY14P2RY6P2RY2P2RY4OGT | |
| SCHEMBL1521296 | 1.00 | P2RY14 (1.00) | P2RY14P2RY6P2RY2P2RY4OGT | |
| SCHEMBL23344493 | 1.00 | P2RY14 (1.00) | P2RY14P2RY6P2RY2P2RY4OGT | |
| SCHEMBL14281873 | 1.00 | P2RY14 (1.00) | P2RY14P2RY6P2RY2P2RY4OGT | |
| SCHEMBL16138527 | 1.00 | P2RY14 (1.00) | P2RY14P2RY6P2RY2P2RY4OGT | |
| SCHEMBL20718791 | 1.00 | P2RY14 (1.00) | P2RY14P2RY6P2RY2P2RY4OGT | |
| SCHEMBL19315974 | 1.00 | P2RY14 (1.00) | P2RY14P2RY6P2RY2P2RY4OGT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 661 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092179-A1 | GENETICALLY MODIFIED HOST CELLS PRODUCING VIOLACEIN, ANALOGUES, AND DERIVATIVES THEREOF | OCTARINE BIO APS (DK) | 2026-04-02 | — | — | US | claimed |
| EP-4702138-A1 | PRODUCTION OF A NEGATIVELY CHARGED OLIGOSACCHARIDE BY A CELL | Inbiose N.V. (BE) | 2026-03-04 | — | — | EP | claimed |
| US-20250388948-A1 | CELL-FREE ENZYMATIC METHOD FOR PREPARATION OF N-GLYCANS | MAX PLANCK GESELLSCHAFT (DE) | 2025-12-25 | — | — | US | claimed |
| EP-4662305-A1 | PRODUCTION OF A DISACCHARIDE AND/OR MILK OLIGOSACCHARIDE BY A CELL WITH REDUCED SYNTHESIS OF UDP-GLCNAC | Inbiose N.V. (BE) | 2025-12-17 | — | — | EP | claimed |
| EP-4662224-A1 | PRODUCTION OF A SACCHARIDE BY A CELL WITH REDUCED SYNTHESIS OF LACTOBIONIC ACID | Inbiose N.V. (BE) | 2025-12-17 | — | — | EP | claimed |
| US-20250333475-A1 | CD44 GLYCOEPITOPES AND CHIMERIC VACCINE GLYCOCONJUGATES FOR CANCER THERAPY AND SYNTHESIS METHODS THEREOF | I3S - INSTITUTO DE INVESTIGAÇÃO E INOVAÇÃO EM SAÚDE, ASSOCIAÇÃO (PT) | 2025-10-30 | — | — | US | claimed |
| EP-4608849-A1 | SACCHARIDE IMPORTERS FOR LACTO-N-TRIOSE | Inbiose N.V. (BE) | 2025-09-03 | — | — | EP | claimed |
| EP-4298237-B1 | SINGLE CELL GLYCAN PROFILING | 10X GENOMICS INC (US) | 2025-06-25 | — | — | EP | claimed |
| CN-116333062-B | SARS-CoV-2 coronavirus glycosylated RBD protein, preparation and application thereof | 山东大学 | 2025-06-17 | — | — | CN | claimed |
| US-20250188506-A1 | ANTICOAGULANT HEPARIN-CHONDROITIN CHIMERIC SACCHARIDE MOLECULE AS WELL AS PREPARATION METHOD AND APPLICATION THEREOF | SHANDONG UNIVERSITY (CN) | 2025-06-12 | — | — | US | claimed |
| WO-2022152915-A1 | EXTRACELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS | INBIOSE N.V. (BE) | 2022-07-21 | — | — | WO | claimed |
| WO-2022152914-A1 | CELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS | INBIOSE N.V. (BE) | 2022-07-21 | — | — | WO | claimed |
| CN-114703242-A | Double-enzyme co-immobilization synthesis method of uridine diphosphate-N-acetylglucosamine and derivatives thereof | 山东大学 | 2022-07-05 | — | — | CN | claimed |
| WO-2022129470-A1 | VARIANT SUCROSE PERMEASE POLYPEPTIDES | INBIOSE N.V. (BE) | 2022-06-23 | — | — | WO | claimed |
| WO-2022119982-A2 | MODULAR GLYCAN PRODUCTION WITH IMMOBILIZED BIONANOCATALYSTS | ZYMTRONIX CATALYTIC SYSTEMS, INC. (US) | 2022-06-09 | — | — | WO | claimed |
| CN-114207108-A | Genetically modified host cells producing glycosylated cannabinoids | 奥克塔林生物制剂公司 | 2022-03-18 | — | — | CN | claimed |
| WO-2022034077-A1 | PRODUCTION OF ALPHA-1,3 GLYCOSYLATED FORM OF FUC-A1,2-GAL-R | INBIOSE N.V. (BE) | 2022-02-17 | — | — | WO | claimed |
| WO-2022034076-A2 | PRODUCTION OF GALACTOSYLATED DI- AND OLIGOSACCHARIDES | INBIOSE N.V. (BE) | 2022-02-17 | — | — | WO | claimed |
| WO-2022034075-A1 | PRODUCTION OF GLCNAC CONTAINING BIOPRODUCTS IN A CELL | INBIOSE N.V. (BE) | 2022-02-17 | — | — | WO | claimed |
| WO-2022034069-A1 | PRODUCTION OF A MIXTURE OF NEUTRAL FUCOSYLATED OLIGOSACCHARIDES BY A CELL | INBIOSE N.V. (BE) | 2022-02-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092179-A1 | GENETICALLY MODIFIED HOST CELLS PRODUCING VIOLACEIN, ANALOGUES, AND DERIVATIVES THEREOF | TDO2, BLVRB, INMT | P2RY14 2873/4885P2RY6 2879/4885P2RY2 3553/4885 |
| US-20250188506-A1 | ANTICOAGULANT HEPARIN-CHONDROITIN CHIMERIC SACCHARIDE MOLECULE AS WELL AS PREPARATION METHOD AND APPLICATION THEREOF | HPSE, CD44, CSGALNACT1 | P2RY14 192/4885P2RY6 623/4885P2RY2 877/4885 |
| US-20250388948-A1 | CELL-FREE ENZYMATIC METHOD FOR PREPARATION OF N-GLYCANS | MAN2A1, ENGASE, MAN2B1 | P2RY14 4526/4885P2RY6 4516/4885P2RY2 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.